Progress in evaluation

Progress in evaluation

Article 54 of REACH requires ECHA to report on the progress made (over the previous year) in dossier and substance evaluation, by 28 February each year.

This reporting consists of numerical data on compliance checks, testing proposal examinations, follow-up assessments and substance evaluations carried out during the previous year.

Later in the year, ECHA also publishes its Integrated Regulatory Strategy report which provides an overview of the activities to improve chemical safety and their impact.

Overall progress from 2009 to 2022

As a result of compliance check, testing proposal examination and substance evaluation, since 2009, ECHA issued more than 3 790 decisions covering approximately 12 200 information requests on more than 2 600 substances. 

An analysis for 2020-2022 revealed that around 20 % of completed dossier evaluation cases were being considered for further regulatory action (harmonised classification and labelling (CLH), endocrine disruptor (ED), and persistent, bioaccumulative and toxic (PBT) assessment or substance evaluation). The most frequent outcome by far was the consideration of a CLH process, particularly for reproductive toxicity concerns.
 

Evaluation progress, 2009-2022

Evaluation process Adopted decisions Information requests Information requests by area
Annex I
(incl. CSR, RSS, PBT)*
Annex VI 
(incl. SID, C&L)*
Physico-chemical Environment Human Health
Compliance check 2 130 8 669 431 579 292 3 629 3 738
Testing proposal examination 1 472 2 834 N/A N/A 164 885 1 785
Substance evaluation ** 194 699 261 22 45 161 210
TOTAL 3 796 12 202 692 601 501 4 675 5 733

* Annex I: General provisions for assessing substances and preparing chemical safety reports (CSR); Annex VI: Information requirements referred to in Article 10 (information to be submitted for general registration purposes); CSR: chemical safety report; RSS: robust study summary; PBT: persistent, bioaccumulative and toxic; SID: substance identification; C&L: classification and labelling.
** The substance evaluation process started in 2012.

EU Privacy Disclaimer

This website uses cookies to ensure you get the best experience on our websites.